Bonviva is contraindicated in patients with known hypersensitivity to ibandronic acid or to any of the excipients. Bonviva is contraindicated in patients with uncorrected hypocalcemia. As with all bisphosphonates indicated in the treatment of osteoporosis, pre-existing hypocalcemia needs to be corrected before initiating therapy with Bonviva. As with several bisphosphonates, Bonviva is contraindicated in patients with abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see Precautions). Bonviva is contraindicated in patients who are unable to stand or sit upright for at least 60 minutes (see Dosage & Administration and Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Manage Account
Change Password
Sign Out
